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Abstract
Background: Probiotics have been studied as immunomodulatory agents of allergy. Several human probiotic trials tracking
the development of eczema and other forms of allergy have yielded inconsistent results. A recent infant study
demonstrated that pre and postnatal Lactobacillus rhamnosus HN001 (HN001) supplementation decreased the prevalence
of eczema and IgE associated eczema. However, the influence of HN001 on the incidence of wheeze, asthma, and/or other
allergic manifestations has yet to be reported.
Objective: This study was conducted to determine the effects of the probiotic HN001 on the development of allergic lung
disease in a pig model.
Methods: Allergy was induced by a series of subcutaneous and intratracheal sensitizations with Ascaris suum allergen (ASA)
during a six week time frame in post-weanling pigs supplemented daily with HN001, or without supplementation. One
week following final sensitization intradermal skin tests and respiratory challenges were conducted.
Results: In response to intradermal and respiratory challenges, ASA-sensitized pigs fed HN001 had less severe skin flare
reactions, smaller increases in pleural pressure, and trends towards lower changes in arterial oxygen and carbon dioxide
partial pressure levels compared to control pigs. The frequency of ASA-specific IFN-c-secreting peripheral blood
mononuclear cells, as well as the amount of IL-10 produced by ASA-specific cells, was of greater magnitude in probiotic-fed
pigs compared to control animals. These observations suggest that differences in clinical responses to the allergen
challenges may be related to probiotic-induced modulation of Th1 (IFN-c) and regulatory (IL-10) cytokine expression.
Conclusions: Probiotic supplementation decreased the severity of allergic skin and lung responses in allergen-sensitized
pigs with a corresponding increase in IFN-c expression. A similar correlation between certain allergic responses and
increased IFN-c expression has been reported in human clinical studies of allergy; this pig model of allergy may be indicative
of potential probiotic modulation of allergic lung disease in humans.
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Introduction
Probiotics have been studied as mucosal immune modulators
targeting allergy outcomes. Several human probiotic trials tracking
eczema and other forms of allergy have yielded inconsistent results
[1,2,3,4,5,6]. Interestingly, two studies using the same probiotic,
Lactobacillus rhamnosus GG, with similar study designs, resulted in
different outcomes; either a decrease in eczema was observed [1]
or no probiotic benefit was reported [5]. Furthermore, a follow-up
report indicated the initial decrease in eczema in at risk infants
supplemented with the probiotic Lactobacillus rhamnosus GG was
accompanied by the tendency of increased wheeze in this group at
7 years of age [7]. In a study using Lactobacillus acidophilus LAVRI-
A1 there was no probiotic-associated decrease in atopic dermatitis,
but there was significantly more allergen sensitization and an
increase in wheeze in supplemented infants [4]. In a more recent
infant clinical study, Lactobacillus rhamnosus HN001 (HN001) was
supplemented prenatally to expectant mothers of at risk infants,
and antenatally to their infants. Mothers received the probiotic
supplementation from 2-4 weeks prior to delivery and continued
the supplementation through the next 6 months if breast-feeding.
Regardless, infants were supplemented from birth through the first
2 years of life. Results from this trial indicated that HN001
decreased the prevalence of eczema and of IgE-associated eczema
in the study population at 24 months of age compared to age-
matched controls (p=0.01 and p= 0.04 respectively) [8].
The influence of HN001 on the incidence of wheeze, asthma,
and/or other allergic manifestations has yet to be reported.
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2Therefore, our objective was to determine if this probiotic
(HN001) would modulate allergic reactions in a positive or
negative manner. To this end, we modified a porcine model used
to study allergic airway reactions [9] so that the effect of HN001
on the immediate lung and skin allergic responses could be
evaluated.
Briefly, starting at 3 weeks of age, pigs were divided into two
groups, one of which received supplementation with the probiotic
HN001. At this time, both groups of animals were injected
subcutaneously with allergen from the endoparasitic roundworm,
Ascaris suum. During the ensuing 6 weeks, all animals were
sensitized three more times via subcutaneous and twice by
intratracheal routes with the allergen. At seven weeks from the
initial sensitization, the pigs were challenged via intradermal and
intratracheal administration of the allergen. Using this pig model
of allergy we demonstrated the ability to induce allergic
manifestations of immediate skin hypersensitivity and allergic lung
disease in pigs, as well as a reduction in the severity of both of these
allergic manifestations via probiotic intervention.
Materials and Methods
Ethics Statement
This study was approved by the Institutional Animal Care and
Usage Committee of the University of Illinois, number 09312, and
conducted in compliance with local and federal guidelines
regulating laboratory animal care and housing.
Animals
Twelve specific pathogen free hybrid (Duroc [boar] x
Yorkshire/Landrace [sow]) pigs of comparable weights were
obtained from six litters at the University of Illinois Veterinary
Medicine Research Farm. Pigs were sow-reared for the first 21
days of life, then weaned to creep feed, and from day 35 forward
fed adult pig chow (University of Illinois Feed Mill, Champaign,
IL). Pigs were housed in accordance with standard animal usage,
maintained on 12 hour light/dark cycles, and had free access to
water and study feeds. Pigs were weighed after weaning and at
various times during the ensuing 49 days as an assessment of
health status.
Probiotic and probiotic treatment
At the onset of weaning (study day 21), pigs were assigned to
either the control (n=6) or probiotic-treated group (n=6) with
equal litter representation between study groups. Members of the
latter group were individually fed a daily dose of ,1610
10 colony
forming units of the probiotic, HN001 (Danisco, Madison, WI)
that had been mixed with a small amount of vanilla pudding.
Because pigs like vanilla flavoring, they immediately ate the
probiotic-modified pudding assuring that each pig received its
daily probiotic dose. Control group animals received vanilla
pudding lacking the probiotic.
Allergy induction
This model of allergic lung disease is a modification of that
reported by Fornhem et al. [9]. Pigs were sensitized on study days
21, 35, and 49 by subcutaneous injection into the posterior section
of the hind leg with 1.0 mg Ascaris suum allergen (ASA, Greer
Laboratories, Lenoir, NC) plus alum (0.5 mL of 10% alum per
10 mg of protein) in 2 mL of saline. Moreover, on study days 49
and 63, 1.0 mg ASA without alum in 5 mL saline was
administered to each animal, instilled at the level of their lower
trachea, with a nebulizer, via an endotracheal tube. These
procedures were performed under anesthesia induced by an
intramuscular injection of a solution containing TelazolH,
ketamine, and xylazine at 4.4, 2.2, and 2.2 mg/kg body weight,
respectively.
Intradermal ASA challenge and evaluation of the
response
Following an overnight fast, pigs were anesthetized on study
days 45 and 70 as described above. Challenge consisted of a line of
intradermal injections at 11 sites from anterior to posterior on pigs’
abdomens. One hundred microliters of each 2-fold ASA serial
dilution, ranging from 400 mg/mL to 0.75 mg/mL, as well as with
saline alone, was injected per site. After 20 minutes, reactions to
the ASA were measured by using ultra-test calipers (General MG,
Japan) to determine the diameter of the flare at the site of allergen
or saline injection.
Respiratory ASA challenge and evaluation of the
response
Respiratory function assessments were performed on study day
70. Anesthesia was induced as previously described and main-
tained by a continuous intravenous infusion of a mixture of
xylazine (1 mg/mL), ketamine (1 mg/mL) and guaifenesin (5% v/
v) dripping at an approximate rate of 1 mL/kg/h. One of the
control animals had an unexpected and unexplained reaction to
the anesthetic; further testing was not conducted on this pig.
Anesthesia was initiated approximately 1 hour prior to respiratory
challenge to enable arterial and venous vessel catheterization
(saphenous artery and ear vein, respectively) tracheal intubation,
esophageal balloon placement, and measurement of the intrader-
mal responses to ASA. Balloon placement consisted of a balloon
being inserted into the pig’s esophagus through the animal’s
mouth and positioned mid-thorax. After being filled with 1–2 cc of
air, its correct placement was verified by obtaining a representative
pleural pressure curve, according to standard technique [10].
Respiratory challenges were performed within 10 minutes after
recording intradermal allergic responses. Challenges were con-
ducted by using a portable ultrasonic nebulizer. Two point five
milligrams of ASA in 0.5 mL of saline was administered to the
lower airways of spontaneously breathing anesthetized pigs via an
endotracheal tube during a 1 minute period. Blood samples taken
from a catheter placed in the saphenous artery were collected at 0,
2, 5, 10, 20, and 30 minutes post-respiratory challenge. Levels of
arterial blood gases (pO2 and pCO2) in these samples were
determined by using a blood gas analyzer (Rapidlab 855, Bayer
[now Siemens Medical Solutions Diagnostics, Tarrytown, NY]).
As a precaution, injectable epinephrine was available to counteract
anaphylactic reactions, however; the use of epinephrine was not
necessary.
Lung function was assessed as previously described [11] with
modifications. Briefly, tracheal airflow was measured with a
pneumotachygraph (TSD137G, Biopac Systems, Inc. Goleta, CA),
connected to a differential pressure transducer (TSD160B, Biopac
Systems). Pleural pressure (Pp) was measured via the esophageal
balloon connected to a pressure transducer (TSD104A, Biopac
Systems). The airflow and Pp signals were amplified using a
transducer amplifier (DA100C, Biopac Systems) and then sent to
an acquisition and analysis system (MP150, Biopac Systems) which
recorded and analyzed the signals continuously from 2 minutes
before to 30 minutes after the respiratory challenge. These
recordings were used to calculate the lung resistance (RL; mmHg/
mL second) and dynamic lung compliance (Cdyn; mL/mmHg)
using the AcqKnowledge software (Biopac Systems, Inc). Average
values from data encompassing at least 30 seconds of continuous
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challenge.
Quantitation of cytokine secretion by peripheral blood
mononuclear cells (PBMCs) by ELISA
Blood was collected from the pigs’ jugular veins on study days
35, 49, 63, and 70 and PBMCs from these samples were isolated
using standard density gradient procedures as described previously
[12]. Ten million cells from each animal were cultured in
individual wells of a 24-well plate in RPMI medium supplemented
with 5% fetal porcine serum [12] in the presence or absence of
10 mg/mL ASA for 24 hours at 37uC in a 5% CO2 atmosphere.
Afterwards, the culture supernatants were collected and stored at
220uC until tested for the presence of interleukin (IL)-4 and IL-10
by using specific ELISA CytoSet components from Invitrogen
(Carlsbad, CA.) according to manufacturer’s instructions.
Detection of interferon (IFN)-c secreting cells in PBMCs
by ELISPOT
The frequencies of IFN-c secreting PBMCs (PBMCs isolated as
described above) on study days 35, 49, 63, and 70 were
determined by adapting a previously described ELISPOT assay
[12] for use with ASA stimulation. This method utilizes unlabeled
monoclonal antibody (mAb) P2G10 and biotin-labeled, mAb
P2C11 (BD/Pharmingen, San Diego, CA) that are specific for
different epitopes of porcine IFN-c [13]. Briefly, the bottoms of
96-well Immulon II plates (Dynatech, Inc.) were coated with
50 mL per well of 10 mg/mL mAb P2G10 in 0.1 M carbonate
buffer, pH 9.6. After a 4uC overnight incubation, the wells were
washed three times with sterile PBS and then incubated with
50 mL of RPMI medium supplemented with 5% fetal porcine
serum for 2 hours at 37uC in a 5% CO2 atmosphere. Fifty
thousand PBMCs were added per well and exposed to 10 mg/mL
ASA at 37uC in a 5% CO2 atmosphere for 20 hours. Cells were
then removed by washing the wells six times with PBS containing
0.05% Tween-20. Fifty microliters of 0.5 mg/mL biotin-labeled
mAb P2C11 in 0.05% PBS–Tween was added to each well and
plates were incubated for 1 hour at 37uC. After again washing six
times, 50 mL of 0.31 mg/mL streptavidin–horseradish peroxidase
(Zymed; SanFrancisco, CA) was added to each well. Plates were
incubated for 1 hour at 37uC. Excess streptavidin–horseradish
peroxidase was removed by washing the wells three times; 50 mL
of 3,39,5,59-Tetramethylbenzidine membrane peroxidase substrate
(Kirkegaard & Perry Laboratories, Gaithersburg, MD) was added
to each well for 30 minutes at 37uC. Hydrolysis of this compound
results in the development of blue spots whose size and intensity
are directly proportional to the amount of bound IFN-c [12]. The
frequency of ASA-specific IFN-c-producing cells in each sample
was determined by averaging the number of blue spots in duplicate
wells.
Lung assessments
Twenty-four hours after respiratory challenge, pigs were
anesthetized by intramuscular injection, as described above, and
then euthanized by intravenous injection of a 30 mL bolus of a
saturated solution of potassium chloride. Necropsy immediately
followed. Lungs (without trachea and lymph nodes) were removed,
weighed, and the accessory lobe was lavaged with approximately
120 mL of sterile phosphate buffered saline. Cell counts from
bronchoalveolarlavage (BAL)fluidwere performed withaCell-Dyn
3700 (Abbott Diagnostics, Chicago, IL) and leukocyte differential
counts were determined by microscopic analyses of Giemsa stained
cytospin preparations. See Figure 1 for study design.
Statistical Analysis
Repeated measures analysis of variance of intradermal response
data between groups was performed using SAS software, Version
9.1 (Cary, NC). Student’s t tests for each allergen concentration
Figure 1. Schematic representation of study design. The entire 70 day process involving the transtition from weaning to adult food intake, the
onset and continuation of probiotic supplementation, the subcutaneous (SC) and intratracheal (IT) introduction of ASA plus alum and ASA without
alum (ASA/alum and ASA, respectively) at 1 mg doses/pig, and the intradermal and respiratory challenges with ASA is delineated.
doi:10.1371/journal.pone.0016577.g001
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variance, Excel Software 2003). Student’s t tests were performed
within groups comparing the extent of skin flare reactions at study
day 45 to study day 70 (paired, 2-tailed, equal variance, Excel
Software 2003).
Lung function was assessed to determine recovery from
challenge and/or severity of reaction. Each measurement at 2,
5, 10, 20, and 30 minutes post-respiratory challenge was compared
to the respective baseline result (0 minutes post-challenge; each pig
served as its own control) to identify change over time within each
group (Student’s t tests, paired, 2-tailed, equal variance). As the
biological variation in allergic phenotype among litters is typically
great, it was necessary to normalize the biological variation of the
lung assessments for comparisons between the two groups.
Therefore, the percent change of each lung function assessment
was analyzed by repeated measures analysis of variance and at
each time-point by Student’s t test (unpaired, 2-tailed, equal
variance). The percent change was calculated by subtracting the
baseline value from the value at a given time-point, dividing by the
baseline value, and then multiplying by 100%.
Cytokine data were analyzed by Student’s t test (paired, 2-tailed,
equal variance) comparing days 49, 65, and 70, to day 35 within
groups and also between groups by repeated measures of variance
analysis and by Student’s t tests (unpaired, 2-tailed, equal variance)
at each time-point. Due to the small number of animals per group,
statistically significant values (p-value #0.05) or trends/tendencies
towards significance (0.051#p-value #0.1) were interpreted as
suggestive.
Results
Characterization of skin and lung histological changes in
non-sensitized and ASA-sensitized pigs after exposure to
ASA
In previous non-interventionstudies pigs sensitized with ASAand
challenged intradermally or intratracheally with ovalbumin, or
animals mock sensitized with phosphate buffered saline and
challenged in a similar manner with ASA, did not exhibit dermal
or respiratory reactions (data not shown). In contrast, an ASA
intradermalchallenge to ASA-sensitized animals is associated witha
typical dermal inflammatory response that is characterized by
reddening of the injection site within 5 minutes of exposure. The
flare intensity increases, peaking by 20 minutes, and gradually
wanes thereafter. To establish the nature of the skin flare response,
tissue samples from reactive sites of several ASA-sensitized pigs
challenged intradermally with 40 mg ASA 20 minutes earlier were
stained with hematoxylin and eosin and examined microscopically.
Histological evaluation of reactive skin sites indicated marked
dermal and subcutaneous edema as well as perivascular infiltration
by lymphocytes and eosinophils (data not shown). A similar
examination of lung tissue samples from ASA intratracheally
challenged pigs demonstrated the infiltration of eosinophils into the
lamina propria of airway epithelium in ASA-sensitized animals only
and not inASA-naı ¨vepigs (Figure2A & B).Eosinophilinfiltrationof
tissues is a hallmark of allergic responses and lung eosinophilia has
been implicated as a factor of lung remodeling in asthma [14,15].
Probiotic supplementation diminished allergic skin flare
responses to intradermal challenge with ASA in ASA-
sensitized pigs
In the current study, the extent of skin flare responses in the
ASA-sensitized pigs to intradermal challenges with ASA were
compared on a group and temporal basis to determine any
influence due to probiotic supplementation or additional exposure
to the allergen. There was no detectable difference in the degree of
skin flare responses between the two groups on study day 45.
However, after an interval of 25 days (study day 70) which
encompassed two additional exposures to ASA (Figure 1), control
pigs developed more severe reactions to allergen doses of 400 mg/
mL (p=0.024), 200 mg/mL (p=0.005), 100 mg/mL (p=0.027),
50 mg/mL (p=0.024), and 25 mg/mL (p=0.066 [trend]) than
probiotic fed animals (Figure 3A); when adjusting for multiple
comparisons, the p-value of the 200 mg/mL dose retained
significance. Responses between the two groups to lower allergen
doses were not significantly different (Figure 3A).
The additional exposure to ASA also impacted the severity of
skin flare responses of control pigs; a trend for increased skin flare
responses was seen at allergen doses of 200 mg/mL (p=0.059) and
100 mg/mL (p=0.068) when measured on study day 70 as
compared to study day 45 (Figure 3B). In contrast, at these
concentrations the intensity of this response in probiotic-fed pigs
Figure 2. Lung tissue 24 hours post-respiratory challenge with
ASA. Lungs were removed from a non-sensitized (A) and an ASA-
sensitized (B) pig 24 hours after respiratory challenge, fixed in formalin,
stained with hematoxylin and eosin, and examined with a light
microscope (400X magnification). An increased cellular infiltrate,
composed mainly of eosinophils (cells with a pink cytoplasm
surrounding a blue nucleus), in airway submucosa and lamina propria
is apparent in the tissue from the ASA-sensitized animal as compared to
that from the naı ¨ve pig.
doi:10.1371/journal.pone.0016577.g002
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(Figure 3C). Thus, probiotic supplementation appeared to
attenuate a heightening in severity of skin flare response to the
largest amounts of allergen (Figure 3C). For both groups there was
an increase in skin flare size at the latter study day to allergen doses
of 1.5 and 0.75 mg/mL (p=,0.001,in both groups at both
concentrations, Figures 3B and 3C). Moreover, for the probiotic
group only, an enhancement was also noted at the 3 mg/mL
concentration (p=0.032, Figure 3C). This augmentation in the
allergic response in relation to the low end of both dose response
curves indicated the sensitivity of the skin flare responses increased
with repeated ASA exposure for both groups and that probiotic
supplementation did not influence sensitivity to the allergen.
Probiotic supplementation diminished allergic lung
responses to intratracheal challenge with ASA in ASA-
sensitized pigs
Changes in lung function resulting from the allergen challenge
were assessed by calculating lung resistance (RL) and dynamic
lung compliance (Cdyn) using Pp and air flow recorded values. To
determine the level of peripheral blood oxygenation, arterial blood
gas (pO2 and pCO2) levels were also measured. Simplistically, lung
resistance is a measure of the ease in which air flows through the
respiratory structures, and lung compliance is the ability of the
lung to expand or the ‘‘flexibility’’ of the lung. Increased lung
resistance and decreased lung compliance indicate the lung has
lost ‘‘flexibility’’ or has become ‘‘stiffer’’ due to fibrous tissue, and
in the case of an asthmatic episode, cellular infiltrates, edema, and
bronchi constriction. Increased Pp indicates labored breathing or
respiratory distress, while a drop in arterial pO2 accompanied by
an increase in arterial pCO2 indicates the lung has diminished
capacity to oxygenate and remove CO2 from the blood.
Acute and adverse changes in the lung function of pigs after
intratracheal ASA challenge were observed for both groups
although differences in lung function recovery between the two
groups were noted. A marked increase in RL was observed in all
animals within 5 minutes after being challenged with ASA. While
these values for the probiotic-fed group were not different from
baseline by 20 minutes post-challenge, the RL for control animals
remained elevated through the 30 minute monitoring period
(Table 1). As with RL, Pp, pO2 (trend for difference at 30 minute
time-point), and pCO2 levels returned to baseline values sooner for
the probiotic-fed group than the control group (Table 1). Thus,
probiotic supplementation was associated with a faster return to
normal lung function.
When comparing lung function assessments between groups,
the probiotic-fed pigs exhibited a lower average percent change in
RL from baseline at all time-points as compared to the control
group, but due to the variability among animals, especially in the
control group, the group means were not statistically significant
(Figure 4). No differences in lung Cdyn were noted between
groups (Figure 4). Five minutes post-respiratory challenge the
percent change in Pp (p=0.032, Figure 5), pO2 levels (p=0.075,
Figure 5) and pCO2 levels (p=0.058, Figure 6) was less or tended
to be less in the probiotic-fed group. Ten minutes post-respiratory
challenge, the percent change in pO2 levels (p=0.076, Figure 6)
also tended to be less in the probiotic group. However, there were
no differences between groups in these lung function assessments
by repeated measures analysis.
Taken together, these lung function data suggest that probiotic-
fed pigs developed less severe reactions to the respiratory challenge
and, when negatively affected, returned faster to pre-challenge
status. By the end of the 30 minute monitoring period, the
majority of lung function assessments for pigs in the probiotic-
supplemented group were not different from those recorded as
Figure 3. Skin flare reactions 20 minutes post-intradermal challenge with ASA. ASA-sensitized pigs were intradermally inoculated with the
indicated amounts of ASA. After 20 minutes the diameters of the resultant skin flares at the sites of inoculation were measured. Results are expressed
as mean 6 standard error of mean (SEM) for the respective group of pigs (n=6). (A) Measurements made on study day 70 for control (triangles) and
probiotic-fed (circles) groups. Differences between the responses of the two groups are indicated by * (p#0.05) or { (0.051#p#0.1) and are not
corrected for multiple comparison (Student’s t test, unpaired). (B) Measurements made on study days 45 (open triangles) and 70 (filled triangles) for
the control group. Differences between the responses of this group on day 45 versus day 70 are indicated by * (p#0.05) or { (0.051#p#0.1)
(Student’s t test, paired). (C) Measurements made on study days 45 (open circles) and 70 (filled circles) for the probiotic-fed group. Differences
between the responses of this group on day 45 versus day 70 are indicated by * (p#0.05) (Student’s t test, paired).
doi:10.1371/journal.pone.0016577.g003
Table 1. Lung function recovery: assessments post-respiratory challenge compared to baseline.
Lung function
assessment Study Group
2 minutes post-
challenge (p-value)
5 minutes post-
challenge (p-value)
10 minutes post-
challenge (p-value)
20 minutes post-
challenge (p-value)
30 minutes post-
challenge (p-value)
Lung resistance Control (n=5) 0.070 0.040 0.004 0.026 0.035
Probiotic (n=6) 0.027 0.056 0.058 ND ND
Lung compliance Control (n=5) ND 0.024 0.032 ND ND
Probiotic (n=6) 0.039 0.035 0.047 0.058 ND
Pleural pressure Control (n=5) 0.070 0.005 0.015 0.032 0.006
Probiotic (n=6) 0.026 0.037 0.069 ND ND
pO2 Control (n=5) 0.026 0.001 ,0.001 0.005 0.018
Probiotic (n=6) 0.010 0.002 ,0.001 0.005 0.065
pCO2 Control (n=5) 0.052 0.057 0.031 ND ND
Probiotic (n=6) ND ND ND ND ND
Bolded values = significant differences from baseline, italicized values = trends for differences from baseline, ND = not different (significant or trend) from baseline
indicating recovery of lung function.
doi:10.1371/journal.pone.0016577.t001
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Also, while not determined to be statistically significant based on
repeated measures analyses, there were differences or trends
between control and probiotic-fed groups in some lung response
measurements (Pp, pO2, and pCO2) taken 5 and 10 minutes (pO2)
post-respiratory challenge. Since the greatest response to the
respiratory challenge is at these two time-points, there may be
physiological relevance to differences or trends at these individual
time-points.
Consistent with lung function tests, the average weight of the
control pigs’ lungs (340.70619.68 g) was greater than that of the
probiotic group, (294.5766.27 g, p=0.039), suggesting greater
cellular infiltrate and/or edema/mucous production in response to
allergen. Since there were no differences between groups in
numbers or percentages of leukocytes in BAL samples collected
24 hours post-respiratory challenge (data not shown), inflammatory
cell infiltration of the lung parenchyma as well as accumulation of
fluid may account for the difference noticed in lung weights.
Probiotic supplementation modulated the cytokine
responses of ASA-stimulated PBMCs from ASA-sensitized
pigs
Based on ELISPOT assays, the frequency of cells circulating in
the peripheral blood of the probiotic-fed pigs and responding to
ASA stimulation with IFN-c secretion tended to temporally
increase when measured on study day 49 (p=0.060) and increased
on study day 70 (p=0.049) as compared to study day 35
(Figure 7A). Due to technical error, data from study day 63 is
not available. A similar pattern in IL-10 production by ASA-
stimulated PBMCs from this pig group on study days 49
(p=0.034) and 63 (p=0.059) was noticed (Figure 7B). In contrast,
ASA exposure of PBMCs originating from control animals did not
result in a significant increase in the frequency of IFN-c producing
cells or in IL-10 production at the respective time-points.
Comparisons between groups at individual time-points show that
the frequency of ASA-specific IFN-c producing cells tended to be
greater in probiotic-fed pigs compared to control on study days 49
and 70 (p=0.094 and 0.093, respectively, Figure 7A). A similar
analysis also demonstrated heightened IL-10 responses by ASA-
stimulated PBMCs from probiotic-fed pigs compared to those
from the control animals on study day 63 (p=0.033, Figure 7B).
Measurements of IL-4 synthesis by ASA-stimulated PBMCs were
below the level of quantitation at all time-points. There were no
differences by repeated measures analysis in IFN-c producing cells
or in IL-10 levels.
Pig weights
Pigs were weighed at the study start, study end, and at various
time-points throughout the study as an indication of general pig
Figure 4. Changes in RL and Cdyn post-respiratory challenge with ASA. Lung function parameters of ASA-sensitized pigs were continuously
monitored from 2 minutes before to 30 minutes after animals were intratracheally challenged with ASA on study day 70. Based on at least a 30
second interval of these recordings around the indicated times post-respiratory challenge, the average values for RL and Cdyn were determined and
are presented as the mean 6 SEM percent change relative to the baseline (0 minutes) value for the probiotic-fed pigs (n=6) and control pigs (n=5).
Average percent changes for RL and Cdyn in probiotic-fed pigs (filled and open circles, respectively) and in control animals (filled and open triangles,
respectively) are shown.
doi:10.1371/journal.pone.0016577.g004
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in both groups gained weight in a similar fashion (data not shown).
Discussion
The objective of this study was to determine if the probiotic
Lactobacillus rhamnosus HN001 could modulate Ascaris suum-induced
allergic lung response in a pig model. For sensitization of the pigs
to ASA, we modified the model described by Fornhem et al. [9]
where approximately 88% of the pigs receiving three subcutane-
ous injections of ASA had become sensitized to this allergen.
Because our goal was to assess probiotic-induced prevention of
allergic lung disease or reduction of initial sensitization, it was
necessary to increase the incidence of allergic skin and lung
responses to assure 100% of the study population, with no
intervention, would become sensitized to the allergen. To this end,
the protocol was modified to incorporate, prior to challenge, an
extra skin sensitization and two placements of allergen deep in the
pigs’ lungs via an endotracheal tube. Using this robust method of
sensitization, all pigs in the control group developed severe allergic
skin reactions and moderate to severe respiratory responses,
similar to asthma, upon dermal or aerosol allergen challenge,
respectively. Moreover, these alterations in the frequency and
location of ASA administration enabled a nearly five-fold
reduction in the amount of allergen administered per pig for the
respiratory challenge, from the 14 mg utilized by Fornhem et al [9]
to the 2.5 mg used here. Another departure from the model was
the omission of metyrapone prior to and during respiratory
challenge with ASA. This drug was used by Fornhem et al.t o
combat stress-induced increases in cortisol levels that inhibit late
phase lung responses (9). However, since our interest lies
specifically with early phase lung responses and our initial work
with metyrapone resulted in pig emesis, metyrapone was not
included in our studies.
The respiratory responses of the control pigs after intratracheal
challenge with ASA in this study were consistent with those
reported by Fornhem et al [9]. In both cases, immediate spikes in
airway resistance (Figure 4) were accompanied by downward
spikes in arterial blood pO2 levels (Figure 6) which remained
altered compared to baseline through our 30 minute monitoring
period [9]. In addition, pleural pressures (not reported by
Fornhem et al.) in the control group demonstrated the same
pattern as was seen in airway resistance (Figure 5).
In contrast, pigs in the probiotic-fed group had less severe lung
reactions and recovered more quickly from their adverse responses
to the respiratory challenge. It should be noted that the two groups
were composed of out-bred pigs that exhibit inherently greater
biological variation than would be expected from inbred animals.
Yet, we were still able to demonstrate differences or tendencies in
lung responses in these small numbers of animals that had
undergone an intense allergy induction protocol. While probiotic
supplementation decreased the severity of skin responses to
challenge with the maximal doses of ASA, dermal reactions to
Figure 5. Changes in Pp post-respiratory challenge with ASA. The Pp of ASA-sensitized pigs was continuously monitored from 2 minutes
before to 30 minutes after animals were intratracheally challenged with ASA on study day 70. Based on at least a 30 second interval of these
recordings around the indicated times post-respiratory challenge, the average values for Pp were determined and are presented as the mean 6 SEM
percent change relative to the baseline (0 minutes) value for the probiotic-fed pigs (n=6) and control pigs (n=5). Average percent changes for Pp in
probiotic-fed pigs (filled circles) and in control animals (filled triangles) are shown. A significant difference between the relative percent change in Pp
for the probiotic-fed and control groups is indicated by * (p #0.05) (Student’s t test, unpaired).
doi:10.1371/journal.pone.0016577.g005
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tion did not prevent sensitization to ASA at the levels that were
tested.
It is generally accepted that mechanisms of allergic diseases are
characterized by an imbalance in Th1/Th2 immunity favoring
Th2 responses coupled with aberrations in immune regulation
[16]. Deficient IFN-c (Th1) responses have been reported in
human infants with atopic dermatitis [17] and are also reported to
be early markers of atopic dermatitis [18]. Although the role of
IFN-c in allergic lung disease is controversial, reports indicate that
low levels of IFN-c during the first year of life are associated with
recurrent wheeze and asthma in later years [19,20,21] while the
later phases of chronic inflammation are associated with increased
levels of IFN-c [22].
In this swine model of allergy, the allergic response was
induced by immunizing pigs with an extract from the roundworm
Ascaris suum containing allergens known to elicit strong Th2
responses [23] that had been mixed with alum, an adjuvant
classically used to further enhance the intensity of Th2 responses.
Although the frequency of ASA-specific IFN-c secreting cells of
the control animals remained relatively constant during the last
35 days of the study, pigs in the probiotic-fed group tended to
increase the number of these Th1 type responders in their blood.
This trend towards a probiotic-associated boost in IFN-c
production in pigs is consistent with results from human infant
studies demonstrating probiotic-associated increases in IFN-c
from PBMCs [6,24,25] or cord plasma [26] coupled with
decreases in allergic outcomes of atopic dermatitis [2,6,7] and
cow milk allergy [24]. Moreover, in those studies where probiotic
supplementation was not efficacious against allergy [3,4,5], no
probiotic-associated increases in IFN-c were observed [3,18,27].
Together, these studies suggest that a probiotic-promoted
increase in IFN-c production may be one mechanism responsible
for the reduced severity of allergic disease in humans. However,
to date, decreased asthma development in humans as a result of
probiotic-associated increases in IFN-c production has yet to be
demonstrated.
Towards the end of the study, ASA-stimulated PBMCs from
pigs in the probiotic-fed group secreted more IL-10 (regulatory
cytokine) compared to those of the control group. As with IFN-c,
deficient IL-10 responses are early markers of atopic dermatitis
[18] and are reported in infants with this disease [17]. However,
there are no reported differences in IL-10 mRNA expression in
cells from high risk wheezy infants compared to low risk and
healthy infants [21]. Nevertheless, the extent of IL-10 synthesis
may be indicative of the type of immune response associated
with effective asthma treatment. Indeed, successful allergen
immunotherapy and corticosteroid therapy is associated with
increased IL-10 production and numbers of Foxp3
+ T regulatory
cells [28]. However, the role of probiotic modulation of IL-10
Figure 6. Changes in pO2 and pCO2 levels post-respiratory challenge with ASA. Saphenous arterial blood samples were collected from
ASA-sensitized pigs at the indicated times prior to and after intratracheal ASA challenge on study day 70. Blood gas levels (pO2 and pCO2) from these
samples were determined and the average values are presented as the mean 6 SEM percent change relative to the baseline (0 minutes) value for the
probiotic-fed pigs (n=6) and control pigs (n=5). Average percent changes for pO2 levels in probiotic-fed pigs (filled circles) and in control animals
(filled triangles) and for pCO2 levels in probiotic-fed pigs (open circles) and in control animals (open triangles) are shown. Differences between the
relative percent change in pO2 and pCO2 levels for the probiotic-fed and control groups is indicated by { (0.051#p #0.1) (Student’s t test, unpaired).
doi:10.1371/journal.pone.0016577.g006
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human probiotic studies, probiotic supplementation either had
no effect on IL-10 production or IL-10 production was not
determined [3,25,26,27].
This is not the first report of probiotic modulation of allergic
lung disease in an animal model. For instance, several mouse
models studying Lactobacillus species of probiotics have demon-
strated dampening of allergic lung responses [29,30,31,32].
However, to our knowledge this is the first report of modulation
of allergic lung disease severity by the probiotic Lactobacillus
rhamnosus HN001 and the first report of probiotic modulation of
allergic lung disease severity in a pig model.
In conclusion, using an intense allergy induction protocol in
pigs, we demonstrated that Lactobacillus rhamnosus HN001 supple-
mentation reduced the severity of allergic lung outcomes and was
accompanied by a tendency of increased Th1 (IFN-c) responses
balanced with increased regulatory responses (IL-10 production) to
the allergen. While no animal allergy model is completely
representative of human allergy, probiotic modulation of immune
responses in this pig allergy model demonstrated similar probiotic
modulation of immune responses as was seen in human clinical
trials, and may predict probiotic modulation of allergic lung
responses in humans.
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